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rare disease, is a target for enzyme replacement therapies, yet UCD epidemiology 
data are scarce. The objective of this study is to estimate the prevalence of UCD 
in the 0–17 year-old population in five major European markets (EU5) (France, 
Germany, Italy, Spain, UK). Methods: We designed an incidence-survival model 
utilizing birth incidence, annual life-expectancy and country-specific newborn 
data. Birth incidence estimates for UCD were obtained from the Urea Cycle 
Disorders Consortium (UCDC). We conducted a literature review to determine 
the annual life expectancy of UCD. Finally, we reviewed available EU5 newborn 
census data to obtain the number of newborns in each country from 2001 to 2012. 
We extrapolated the trend from 2001-2012 to forecast the number of newborns 
through 2024. These data were entered into the incidence-survival model to calcu-
late the prevalence of UCD from 2015-2024. Results: We estimated a prevalence 
of 1.71 per 100,000 population in the 0–17 year age groups resulting in 1,027 and 
1,033 UCD cases in the EU5 in 2015 and 2024, respectively. The prevalence was 1.89 
per 100,000 in the 0-4 year-old age group, 1.63 per 100,000 in the 10-14 year-old 
age group, and 1.57 per 100,000 in 15-17 year-old age group. ConClusions: To 
our knowledge, this study provides the first prevalence estimate of UCD in the 
EU5 markets. With 1,027 estimated cases in 2015, it is expected that UCD treat-
ments will be expensive given the small size of the patient population. Further, 
these estimates can be used to approximate the total cost burden of UCD and the 
resulting cost-effectiveness of UCD treatments.
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objeCtives: To explore the relationships between characteristics of patients 
with multiple myeloma (MM) and clinical and economic outcomes to identify 
which patient subgroups contribute the greatest clinical and economic bur-
dens. Methods: Literature was systematically searched for relevant articles pub-
lished between 2004 and 2014. A database of patient characteristics, outcomes and 
subgroup-specific information was created and analysed to explore relationships 
between patient characteristics and outcomes. The coefficient of determination 
(R2) was calculated to examine the strength of these relationships to help to formu-
late hypotheses for further research. Results: Objective response rate (ORR) and 
overall survival (OS) were the most commonly reported outcomes, while economic 
outcomes data were limited. Although patient characteristics varied across studies, 
several trends were observed. There was a weak correlation between increasing 
age and higher OS (R2 = 0.0185) and ORR (R2 = 0.0305). OS decreased (R2 = 0.2428) 
as the proportion of patients with International Staging System (ISS) stage III MM 
increased; however, only five studies reported OS by ISS subgroup. ORR decreased (R2 
= 0.2843) as the proportions of patients with no prior stem cell transplantation (SCT) 
increased and a small decrease in OS was observed (R2 = 0.0280), but SCT eligibility 
did not demonstrate consistent outcome trends. A trend towards increased OS was 
seen with previous treatment with bortezomib (R2 = 0.3057) or thalidomide (R2 = 
0.2612). In contrast, previous treatment with these agents was associated with a 
worse ORR (R2 = 0.1926 and R2 = 0.2617, respectively). ConClusions: SCT status 
and prior therapies appear to affect outcomes, and a trend was seen between ISS 
stage III MM and poor prognosis. This exploratory approach has generated hypoth-
eses for further research into how patient characteristics influence resource use 
and cost. A better understanding of how patient factors impact on outcomes may 
facilitate better targeting of treatment.
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objeCtives: The objective of the study was to provide a comprehensive overview 
of existing risk prediction models of mortality, complications, and remission of 
diabetes after bariatric surgery. Methods: A systematic literature review was 
performed in Medline, Medline-In-Process, EMBASE, and the Cochrane Central 
Register of Controlled Trials (CENTRAL) databases in April 2015. All English lan-
guage full-text published derivation and validation studies for risk prediction mod-
els focusing on safety and diabetes outcomes of bariatric surgery were included. 
Two reviewers independently performed screening of the studies. Data extraction 
included population, outcomes, variables, intervention, model discrimination, 
and calibration. Results: Of the 2331 studies retrieved from the search, only 
25 studies met the inclusion criteria. Of these, 20 presented development of risk 
prediction models/scores, and five reported validation of existing models. Six 
models were each developed to predict mortality (in-hospital, at 30 days, 90 days, 
and ten years), complications (during perioperative, at 30 days, and 90 days), and 
remission of type 2 diabetes (post-operative, and at one year); and two models 
developed to predict both mortality and complications (at 30 days). Internal valida-
tion using bootstrap resampling or tenfold validation was reported for six models, 
while five models had external validation using independent patient cohorts: 
ABCD score (remission of type 2 diabetes at one year), DiaRem Score (remission 
of type 2 diabetes at one year), Gupta’s model (remission of type 2 diabetes at one 
year), Maciejewski’s model (complication at 90 days), and OS-MRS (mortality at 
90 days). Models included on average 6.9±3.5 variables (range 2-13). Calibration 
and discrimination statistics were not reported for all models. ConClusions: 
There are a variety of risk prediction models for safety and diabetes outcomes of 
bariatric surgery available. However, only few models have undergone external 
group 15-45 were included for study. According to WHO, anemia in non-pregnant 
women age 15-45 years were classified as mild (110-119g/l), moderate (80-109g/l) 
and severe (less than 80g/l) on the basis of hemoglobin concentration. Results: 
A total of six studies satisfy the inclusion criteria were included for study purpose. 
It includes a total of 4684 anemic women ranging from 26 to 3835 from different 
rural and urban parts of India. The overall prevalence of anemia from the pooled 
estimates was 53.2% (95% CI, 41.1-64.9). Prevalence in rural and urban parts of India 
was found to be 55.2% (95% CI, 12.6-41.5) and 49.5% (95% CI 32.9-66.3), respectively. 
Among all the anemic patients cases, mild 31.6% (95% CI, 30.2-33.0) contributes 
maximum number of patients followed by moderate 19.3% (95% CI, 18.1-20.6), and 
severe 2.2% (95% CI, 1.8-2.7). ConClusions: Anemia is highly prevalent in Indian 
women. Nearly equal prevalence was reported from both rural and urban women 
population. Mild form of anemia was found to be more prevalent.
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objeCtives: Anemia and iron deficiency are common during pregnancy and 
expose mothers to several risks such lower resistance to infections or reduced 
tolerance to significant blood loss and to surgical interventions during labor. 
Regarding the foetus, presumed risks include unfavourable obstetric outcomes, 
notably, premature birth, low birth weight and fetal death. The present study aims 
at exploring the prevalence of iron deficiency and anemia among pregnant women 
in France and at evaluating the management of these conditions. Methods: A 
prospective observational study was conducted in France between March 2013 and 
June 2014. Randomly selected investigators (gynecologists, obstetricians, midwives 
registered in the CEGEDIM® database) were asked to include consecutive pregnant 
women presenting for a consultation. At study inclusion, a two-section question-
naire was completed by both the patient (self-assessment) and the investigator. 
Data collected consisted in age, gestation week, laboratory values (e.g. Hb, fer-
ritin), type and reason for the prescription of medication and lifestyle or dietary 
advice given/received. Results: 1506 patients were enrolled by 95 centres and 
data were analyzed for 1478 women. Investigators estimated that almost 60% of 
women were at moderate or significant risk of iron deficiency. Ferritin levels was 
< 15 µg/L in 30.9% of individuals (18.7%, 31.7% and 51.2% at the 1st, 2nd and 3rd 
trimesters, respectively) and the overall prevalence of anemia was 15.8%. However, 
the proportions of these conditions increased with longer pregnancy duration. 
Medication for iron deficiency was prescribed to 57.3% of patients. 98.5% of anae-
mic women and respectively 97.8% and 73.6% of women at significant or moderate 
risk of iron deficiency were prescribed medications (most iron-based). Among 
women receiving treatment, 43.1% had clinical signs of anemia and 39.3% received 
systematic prevention iron . ConClusions: In French clinical practice, the iron 
deficiency isk and anemia prevalence during pregnancy align with medical 
expectations. These conditions are managed according to national/international 
recommendations.
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objeCtives: Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) is a rare, 
progressive, debilitating and life-threatening neurodegenerative disease. Although 
a rare disease, Portugal has one of the largest TTR-FAP foci in the world but recent 
Portuguese epidemiological data is lacking. The purpose of this study was to esti-
mate TTR-FAP prevalence in Portugal. Methods: TTR-FAP patient’s medicines utili-
zation is fully funded by National Health System in Portugal since 2001. Since March 
2013 Portuguese electronic prescription system became more generalized, allowing 
central monitoring and validation of medicines prescription and dispensing. TTR-
FAP anonymized patient’s data was requested to Administração Central do Sistema 
Saúde (ACSS). The most frequent municipality used for medicines dispensing by 
each patient was identified and used as a proxy for residence. Portuguese popula-
tion by municipality was obtained from Instituto Nacional Estatística. Prevalence 
was reported at country level and by municipality as number of cases per 100 000 
inhabitants. Results: Over the year 2014, two thousand and thirteen (2 013) TTR-
FAP anonymized patients were registered in ACSS database. A prevalence of 20 
per100 000 inhabitants was estimated for TTR-FAP in mainland Portugal. The dis-
ease is spread across 160 of the 278 Portuguese mainland Portuguese municipali-
ties. The municipalities with higher TTR-FAP prevalence are: Póvoa de Varzim (198), 
Pampilhosa da Serra (191), Seia (170), Esposende (138), Vila do Conde (136), Figueira 
da Foz (134), Boticas (111) and Barcelos (110). ConClusions: We can conclude 
that Portuguese ACSS electronic prescription database is useful, relevant and an 
accessible strategy to estimate the prevalence of some diseases in Portugal. We can 
estimate that TTR-FAP disease has a prevalence of 20 per 100 000 inhabitants and 
it is disseminated across the country being Póvoa de Varzim historically and still 
the most impacted municipality with 198 cases per 100 000 inhabitants, nearly ten 
times higher than country prevalence.
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objeCtives: Gene therapies for rare diseases have ignited industry-wide debates 
concerning patient access, pricing and efficacy. Urea cycle disorder (UCD), a genetic 
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in treatment and prophylaxis of patients with von Willebrand disease is approved 
from a pharmacoeconomic point of view.
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objeCtives: The purpose was to estimate the financial consequences of reimburse-
ment of dasatinib in adult population with Ph+ ALL with resistance or intolerance 
to prior therapy in Poland. Methods: The budget impact model was developed 
to evaluate the consequence for National Health Fund budget in Poland in case 
of reimbursement of dasatinib. Two scenarios were considered: with and with-
out dasatinib reimbursement in two-years’ time horizon (2015-2016). In scenario 
with reimbursement, dasatinib would be used instead the FLAM chemotherapy 
(fludarabine, cytarabine, mitoxantrone). Based on the Polish epidemiological data 
the target population – adult patients Ph+ ALL with resistance or intolerance to 
prior therapy – was estimated at 12 patients in one year (with range from 5 to 24). 
Direct medical costs: substances and their administration (assessed chemothera-
pies), monitoring, allogeneic hematopoietic stem cell transplantation (allo-HSCT), 
monitoring after allo-HSCT and palliative care were considered. All calculations 
were performed with the Excel model constructed for economic evaluation and 
budget impact assessment. Results: If the reimbursement of dasatinib is intro-
duced, the annual expenses from the budget of National Health Fund in Poland 
would increase by € 127,279 in the first year and € 189,224 in the second year of reim-
bursement. However, change from FLAM to dasatinib will decrease the necessity and 
length of hospitalization due to the different administration route. ConClusions: 
Reimbursement of dasatinib in Poland will bring additional costs incurred by public 
payer, however, it will also increase the survival of patients with ultra-rare disease 
which is ALL and consequently improve their quality of life.
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objeCtives: To conduct budget impact analysis (BIA) of canakinumab treatment 
group comparing to symptomatic treatment in retrospective group of patients suf-
fering from Muckle–Wells Syndrome (MWS). Methods: BIA was conducted of the 
canakinumab treatment group versus retrospective group with only symptomatic 
treatment. According to the expert opinion canakinumab treatment accompanied by 
vial sharing and it has been taken into consideration of drug cost therapy. Following 
direct medical costs were also included into analysis and based on expert opinion: 
administration costs, costs of diagnostic laboratory and instrumental procedure, costs 
of inpatient and outpatient visits, costs of treating MWS complications and costs for 
correction adverse events. One-year time horizon was used. Results: Cost of canaki-
numab therapy course was 40,830,937 RUB/ 668,220 EUR for 20 MWS patients within 
1 year. The difference in the required budget funds between canakinumab treatment 
group and retrospective group with symptomatic treatment was 38,787,076 RUB/ 
634,771 EUR for 20 patients within 1 year. Decrease of direct medical costs (excluding 
costs for drug therapy) was obtained in canakinumab treatment group and amounted 
763,705 RUB/ 12,498 EUR for 20 patients within 1 year due to a lower frequency of 
inpatient and outpatient visits, complications of MWS and lower administration costs 
in group treated with canakinumab. ConClusions: Usage of canakinumab in the 
treatment of patients with MWS led to budget spending. However, good efficacy of 
canakinumab helped to reduce direct medical costs for 763,705 RUB/12,498 EUR for 
20 patients within 1 year in canakinumab treatment group.
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objeCtives: Evaluate the current prescription trend in Italy and estimate the 
impact of alternative market hypothesis including the introduction of inflixi-
mab biosimilars. Methods: Biologics currently indicated for psoriasis include 
tumor necrosis factor (TNF)-α inhibitors adalimumab, etanercept, and infliximab, 
as well as the interleukin-12/23 inhibitor ustekinumab. A deterministic Markov 
model was developed to simulate the evolution of bio-naïve psoriatic patients 
in Italy for 3 years. Event rates (mortality, malignancies, infections and MACEs) 
and persistence curves, were modeled for each biologic drug used in first, second 
and third line, basing on published data. Hospitalization costs were calculated 
as average of Italian DRGs weighted for event-related frequency. The cost of a 
dermatological visit was considered every two months and in case of therapy 
switch. All costs were calculated from the perspective of NHS. The current Italian 
market mix of biologic treatments was compared with the total substitution of 
infliximab with its biosimilars combined with ustekinumab increasing its mar-
ket share to 40% at the expenses of the remaining biologics, proportionally to 
their current shares. Results: In the next three years, 515 bionaive patients are 
expected to start a new biological treatment annually. Total cost results in about 
45.7 million Euro for 3 years in the current scenario corresponding to 15,148 Euro/
patient yearly. Increasing in ustekinumab market shares and the introduction of 
infliximab biosimilars lead to estimated annual savings of about 670 Euro/patient 
(1.7 million Euro in 3 years). Cost of biologic therapy is the main driver, while der-
matological visits and adverse events management represent less than 1% of the 
total cost. ConClusions: Biological treatment cost of psoriasis depends almost 
completely from pharmacological therapy. Changes in the current prescription 
validation. Further research about the value and accuracy of existing instruments 
in clinical practice is required.
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objeCtives: The UK population is ageing, and the prevalence of obesity is increas-
ing. To assess the likely impact of these two demographic trends, we used a sto-
chastic all-cause, cause of death mortality model to determine changes in likely 
age of death associated with different body mass index (BMI) values in older 
adults. Methods: The Sonata Vivo model adjusts population baseline mortality 
for known risk factors to calculate the mean age of death and most likely causes 
of death for an individual, and has been validated against long-term cohorts in the 
UK and USA. We used the model to calculate the difference in mean ages of death 
at BMIs of 27, 33, 37 and 42 compared with a BMI of 22 in men and women aged 55 
to 90. We assumed all subjects were non-smokers with population average values 
for blood pressure, cholesterol and alcohol consumption. Results: In adults aged 
55 years at baseline, increasing BMI from 22 to 42 was associated with a decrease 
in mean age of death of 1.93 years in women and 1.89 years in men. The absolute 
difference in life expectancy across the BMI range decreased with increasing age 
at baseline, to 0.34 years in women and 0.15 years in men aged 90. As expected, 
the model predicts a longer life expectancy in women than men at each age and 
BMI, but the relative difference between genders was smaller in those with a BMI 
of 42 than in those with a BMI of 22. Analysis by likely cause of death in 55 year old 
adults showed the main impact of obesity was on cardiovascular (CVD) and cancer 
deaths in women, and CVD and endocrine deaths in men. ConClusions: Obesity 
is likely to reduce life expectancy by up to 2 years in older adults in the UK, mainly 
from increased CVD mortality.
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objeCtives: The aim of this study was to evaluate the Budget Impact (BI) of 
treatment of Crohn’s disease with adalimumab (ADA) from the perspective of the 
Brazilian Private Health Care System (BPHCS) over a 5 year time period. Methods: 
An epidemiological model based on the Private Health Care System population, 
DataSUS database and published literature was developed to estimate eligible 
patients in the next five years. The BI was simulated comparing the current sce-
nario (patients treated with intravenous infliximab [IFX]) with a new scenario 
(the introduction of ADA for Crohn’s disease treatment), BPHCS perspective. The 
market-share for ADA starts at 20% during the first year and rises to 80%. Dose per 
application, number of vial/syringe, cost of application and median of weight were 
based on scientific literature. The drug prices were based on Factory Prices plus 
18% taxes from CMED. A deterministic sensitivity analysis (DSA) was performed 
to determinate the impacts in results. Results: 10,035 patients were eligible 
for treatment with either IFX or ADA over the five years of analysis. In the base 
case scenario, the Budget Impact simulation presented a decrease of total cost 
by R$1,942,434.38 in the first year and reached a decrease of R$9,089,493.93 in the 
fifth year. The cumulative economic savings for the five years in the simulation 
with ADA introduction was R$26,879,457.87. In deterministic sensitivity analysis 
cost per vial of IFX, cost per syringe of ADA and market-share of patients were the 
most important variables that impacted results. A majority of DSA scenarios indi-
cated that treatment with ADA provides cost savings. ConClusions: The utiliza-
tion of ADA may generate economic savings for the Brazilian Private Health Care 
System that may allow more eligible patients with Crohn’s disease to be treated 
with ADA.
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the tReatment of von willeBRand diSeaSe
Yagudina R, Kulikov A, Babiy VV
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To conduct a budget impact analysis of treatment and prophylaxis 
of acute bleedings among patients with von Willebrand disease using blood clot-
ting factor concentrates (clotting factor VIII + von Willebrand factor) in the Russian 
Federation. Methods: Clinical effectiveness assessment was based on the results of 
modeling of the treatment and prophylaxis of patients with von Willebrand disease 
using blood clotting factor concentrates (clotting factor VIII + von Willebrand factor) 
within one year (time horizon). The required data was obtained from literature review 
within PubMed and E-library, and from experts in hematological healthcare centers 
in Russia. Cost analysis included assessment of direct and indirect costs that can 
be associated with analyzed schemes of treatment (“No prophylaxis”, “Prophylaxis 
¹1” – median purity concentrate VWF:RCo/FVIII= 0,5/1, “Prophylaxis ¹2” - high purity 
concentrate VWF:RCo/FVIII= 2,5/1, “Prophylaxis ¹3” - high purity concentrate VWF:RCo/
FVIII= 0,9/1). Cost data was based on median prices for medicines and medical services 
in National healthcare system in the Russian Federation. Results: In case of switch-
ing from regimens: “No prophylaxis”, “Prophylaxis ¹1”, “Prophylaxis ¹2”, to the regular 
preventive administration with the scheme “Prophylaxis ¹3” total costs per all popula-
tion within one year can be reduced by 21906000 rubles ($ 396 360), 22143000 rubles 
($ 400 648) and 5752000 rubles ($ 104 075), respectively. ConClusions: Obtained 
results demonstrates that the use of high purity concentrate VWF:RCo /FVIII= 0,9/1 
